

# Pressure BioSciences, Inc.

11:32 30 Jun 2020

## Pressure BioSciences and Leica Microsystems team up to co-market pivotal cancer workflow technology

Pressure BioSciences Inc (OTCQB:PPIO) announced Tuesday it had signed a milestone agreement with Germany's Leica Microsystems CMS GmbH to co-market technology that analyzes proteins from cancer biopsy samples.

The novel technology platform combines the Leica Laser Microdissection (LMD) system for precise excision of specific, minute sections of biopsy tissue with Pressure BioSciences' Barocycler System based on the firm's pressure cycling technology (PCT) for rapid protein extraction and digestion for sample preparation prior to mass spectrometry analysis.

The integrated biomarker discovery workflow quickly and efficiently collects tissue samples excised by the Leica LMD and then drops the samples into PBI's consumable MicroTubes for rapid PCT processing.

### READ: Pressure BioSciences eyeing around \$2.4 million in 1Q 2021 as it sells its first manufacturing run of BaroShear K45 systems

In a statement, the South Easton, Massachusetts-based company said the alliance is expected to offer "transformative new empowerment" to cancer research worldwide, by integrating the latest enabling technologies in capturing, isolating, and preparing precious biopsy samples for superior analysis of relevant biomarkers of disease state and treatment response.

Pressure BioScience CEO Richard Schumacher told shareholders the company was "delighted" to see PBI's PCT-based Barocycler system featured in a pivotal position in the tumor processing workflow.

"Based on results to date, we believe the number of laboratories worldwide performing laser microdissection followed by mass spectrometric analyses will increase at a steady and significant rate, that our Barocycler system will fulfill a critical part of this workflow, that our combined marketing and sales capabilities will result in increased market exposure and acceptance, and that the adoption of this novel new workflow should result in a measurable increase in Barocycler sales before the end of 2020," Schumacher said in a statement.

### Better understanding of tissue environment

The workflow was developed by acclaimed protein chemist Dr Thomas Conrads, senior director of women's health research in the Inova Women's Service Line and chief scientific officer of the Women's Health Integrated Research Center at Inova Health System.


Integrating LMD, PCT, and mass spectrometry will improve understanding of the complex tissue microenvironment and better enable identification of new biomarkers and could lead to real improvements in certain types of cancers, according to Conrad.

Critical differences between tumor and non-tumor regions can only be deciphered by isolating specific, minute sections

**Price:** 2.3

**Market Cap:** \$8.94 m

#### 1 Year Share Price Graph



February 2020 August 2020 February 2021

#### Share Information

**Code:** PPIO

**Listing:** OTCQB

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.49	1.19

**Sector:** Medical technology & services

**Website:** www.pressurebiosciences.com

#### Company Synopsis:

*Pressure BioSciences Inc. (OTCQB: PPIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.*

action@proactiveinvestors.com

of the areas, Leica Microsystems' head of application management Dr Falk Schlaudraff told investors.

"The combined LMD and PCT systems allow for this separation with high accuracy and speed," Schlaudraff said. "Downstream molecular analysis of the different regions will be meaningful since they can be analyzed separately and not as a mixture."

### **Multi-billion dollar market**

For Pressure BioSciences, the ability to co-market the workflow offers the opportunity to extend the integrated LMD-PCT systems into additional research centers globally that are focused on clinical proteomics, cancer research, biomarker discovery, and precision medicine, according to the firm's global director of sales and marketing Roxana McCloskey.

The global cancer biomarker market is forecasted to reach \$136.5 billion by 2023.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).